(Reuters) - Full data from a late-stage clinical trial of Biogen Idec Inc's experimental multiple sclerosis drug, BG-12, showed robust results across multiple measures and revealed no new safety concerns.

ZURICH (Reuters) - Swiss drugmaker Roche Holding said a mid-phase study found its ocrelizumab drug maintained significant reduction in disease activity for multiple sclerosis patients for almost two years, boosting its chances of success in late-stage trials.

CHICAGO (Reuters) - A targeted antibody treatment was effective at keeping monkeys alive even three days after being exposed to the deadly Hendra virus, a promising sign that the treatment may also work in people, U.S. researchers said on Wednesday.

The search for the world's first malaria vaccine received a boost with the release of early results from a major clinical trial showing it cut risk by about half in African children.

SEATTLE/LONDON (Reuters) -An experimental vaccine from GlaxoSmithKline halved the risk of African children getting malaria in a major clinical trial, making it likely to become the world's first shot against the deadly disease.

(Reuters) - Genetic analysis products maker Sequenom Inc , which had a troubled past related to mishandling of clinical data, launched a prenatal test for Down Syndrome that can eliminate the need for risky, invasive procedures.

NEW YORK (Reuters Health) - Despite some promising early evidence, a new clinical trial suggests that flaxseed may not ease menopausal hot flashes after all.

(Reuters) - Anadys Pharmaceuticals Inc said a mid-stage trial showed that over three-fourths of untreated hepatitis C patients receiving a combination of its drug setrobuvir and the standard of care had undetectable virus levels at week 12.

(Reuters) - An experimental drug being developed by Roche Holding AG removed amyloid plaques from the brains of Alzheimer's disease patients in a small early-stage study, according to data published in the Archives of Neurology, the Swiss drugmaker said on Monday.

NEW YORK (Reuters) - Interest in Dendreon Corp's Provenge vaccine to treat prostate cancer seems to be waning following recent approval of Johnson & Johnson's more-convenient and faster-acting Zytiga treatment, according to some doctors and industry analysts.

BOSTON (Reuters) - Targacept Inc, a small drugmaker that began life inside the bowels of R.J. Reynolds Tobacco Co, has for years been using its understanding of nicotine to develop experimental treatments for depression, schizophrenia and, yes, smoking cessation.

An herbal supplement that is widely sold in the United States and Europe to relieve urinary symptoms in men with an enlarged prostate has no benefit over a placebo, a US study said Tuesday.

NEW YORK (Reuters Health) - There's some evidence that fiber supplements may help children with chronic constipation, but little support for other non-drug remedies, a new research review concludes.

NEW YORK (Reuters Health) - Women who have an electro-acupuncture session as part of their infertility treatment may have a better chance of ultimately having a baby, a new clinical trial suggests.

NEW YORK (Reuters Health) - Women who have an electro-acupuncture session as part of their infertility treatment may have a better chance of ultimately having a baby, a new clinical trial suggests.

STOCKHOLM (Reuters) - C ombining two drugs from Novartis and Pfizer to treat post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, study data showed on Monday.

STOCKHOLM (Reuters) - Women with an aggressive type of advanced breast cancer can live significantly longer without their disease getting worse if they are treated with an experimental "armed antibody" drug from Roche, researchers said on Sunday.

STOCKHOLM (Reuters) - A new skin cancer drug from Roche had "remarkable" results in a mid-stage trial, substantially shrinking tumors and lesions in patients with a potentially fatal type of skin cancer, the Swiss drugmaker said on Saturday.

NEW YORK (Reuters) - The research chief of Roche Holding AG <ROG.VX> said the company's experimental drug to raise "good" HDL cholesterol has the potential to generate annual sales of $10 billion and may have advantages over a rival medicine being developed by Merck & Co Inc <MRK.N>.

(Reuters) - Immunomedics Inc said on Thursday that the U.S. health regulator put a partial hold on the company's pancreatic cancer drug trial after a patient was given an incorrect dose.